Experts’ Hopes for the Future of dMMR Uterine Cancer Treatment

In this exclusive MedPage Today video, Susana Campos, MD, from the Dana-Farber Cancer Institute in Boston, and Richard Penson, MBBS, of Mass General Cancer Center at Massachusetts General Hospital in Boston, discuss how they see uterine cancer treatment evolving in 2024.

Following is a transcript of their remarks:

Campos: In terms of what’s maybe on the horizon for 2024, I think we’d all be very pleased if we could stop using chemotherapy in some individuals. We talked about the uterine cancer arena, and we talked specifically about the deficient MMR [mismatch repair], and these individuals do so incredibly well with immunotherapy.

And the question I think that the next series of trials are going to show us, I hope so, is to see whether or not we can actually rid ourselves of chemotherapy in that patient population. So that’s what I’m hoping for in the next New Year is that maybe actually validates that. Dr. Penson?

Penson: I think your timeline might be a bit difficult for delivering on that in the New Year [laughter], but I think this year was really the year of uterine tumors, as Sue said, and so to have two back-to-back New England Journal articles from the [Society of Gynecologic Oncology] meeting, dostarlimab [Jemperli] and pembrolizumab [Keytruda] arriving as drugs that are part of the new standard of care and the approval of the dostarlimab combination. Just very, very exciting.

Please enable JavaScript to view the

comments powered by Disqus.